Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
about
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity.In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations
P2860
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Evaluation of the psychometric ...... hy questionnaire (QLQ-CIPN20).
@en
type
label
Evaluation of the psychometric ...... hy questionnaire (QLQ-CIPN20).
@en
prefLabel
Evaluation of the psychometric ...... hy questionnaire (QLQ-CIPN20).
@en
P2093
P2860
P1476
Evaluation of the psychometric ...... hy questionnaire (QLQ-CIPN20).
@en
P2093
CI-PeriNomS Group
Floortje Mols
Guido Cavaletti
Jan J Heimans
Lonneke van de Poll-Franse
Neil K Aaronson
Tjeerd J Postma
P2860
P2888
P304
P356
10.1007/S11136-017-1626-1
P577
2017-06-20T00:00:00Z
P6179
1086109281